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The cysteine peptidase cathepsin K is a major player in extracellular proteolysis. Here we describe
the identiﬁcation of the multifunctional extracellular chaperone clusterin as a cathepsin K-binding
protein. Clusterin increases the stability of cathepsin K in dilute solution and in the presence of high
protein concentration. It does not alter the activity of the enzyme but acts as a liberator by prevent-
ing substrate inhibition. Kinetic measurements show that clusterin binds cathepsin K with high
afﬁnity (Kd = 0.5–0.6 nM). Altogether these results provide novel insights into the mechanisms
involved in the ﬁne-tuning of cysteine cathepsin activity in the extracellular space.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cysteine cathepsins are among the major players in extracellu-
lar proteolysis that participate in both physiological and patholog-
ical proteolytic processes. The most extensively studied interacting
partners of cysteine cathepsins are their proteinaceous inhibitors,
such as the cystatins and thyropins [1]. Besides these, several other
non-inhibitory binding partners have been described that can
inﬂuence the behavior of these enzymes under various circum-
stances [2].
Cathepsin K is the principal peptidase involved in bone metab-
olism and its deﬁciency causes a rare genetic disorder called pycn-
odysostosis [3]. The enzyme has received much attention in recent
years as a possible target for osteoporosis therapy and at least two
inhibitors of cathepsin K are currently undergoing clinical trials
with promising results [4,5]. Besides bone resorption, cathepsin K
has been linked to numerous other (patho)physiological processes,
such as embryonic development, thyroid hormone release, tumor
development, atherosclerosis, schizophrenia and obesity [6–8].
Cathepsin K exhibits potent collagenolytic activity that is uniquechemical Societies. Published by E
enzyloxycarbonyl-Phe-Arg-7-
ry and Biochemistry, Faculty
Ljubljana, SI-1000 Ljubljana,
ovinec).among mammalian peptidases [9] and its activity and stability in
the extracellular space are regulated by glycosaminoglycans via
allosteric mechanisms [10,11].
In this paper we identify the extracellular chaperone clusterin
as a novel cathepsin K-binding protein. We show that clusterin
binds and stabilizes cathepsin K at neutral pH without directly
affecting enzyme activity. Also, the interaction of clusterin with
cathepsin K results in liberation from the previously reported inhi-
bition by excess substrate.
2. Materials and methods
2.1. Materials
Recombinant human cathepsin K was produced in Escherichia
coli according to the procedure by Novinec et al. [12]. Enzyme
concentration was determined by active site titration with the
irreversible inhibitor E-64 (trans-epoxysuccinyl-L-leucyl-amido
(4-guanidino) butane; Bachem, Switzerland). The synthetic sub-
strate Z-Phe-Arg-AMC (benzyloxycarbonyl-Phe-Arg-7-amino-4-
methylcoumarin) was from Bachem (Switzerland). Human blood
serum was purchased from the University Hospital Zürich (Swit-
zerland). Human plasma clusterin was purchased from Biovendor
(Czech Republic). Soluble ETNA-elastin was from the Elastin Prod-
ucts Co., Inc. (USA). HiTrap NHS-Sepharose columns were from GE
Healthcare (USA).lsevier B.V. All rights reserved.
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Cathepsin K/E-64-Sepharose was prepared by immobilizing
3 mg of cathepsin K on a 1 ml HiTrap NHS-Sepharose column
according to the manufacturer’s instructions. Prior to the coupling,
the enzyme was inactivated with E-64 in order to minimize the
binding of molecules to the active site. The column, attached to
an ÄKTA Prime apparatus (GE Healthcare), was equilibrated in
50 mM Hepes buffer pH 7.40 containing 0.5 M NaCl and 0.05% v/
v Triton X-100. Human blood serum was diluted 1:1 with
100 mM Hepes buffer pH 7.40 containing 1 M NaCl and 0.1% Triton
X-100 and 100 ml of the dilution applied to the column at a ﬂow
rate of 0.5 ml/min. The column was then thoroughly washed with
50 mM Hepes buffer pH 7.40 containing 1 M NaCl and 0.05% v/v
Triton X-100 and bound proteins eluted from the column succes-
sively with 100 mM sodium citrate buffer pH 5.00 containing
150 mM NaCl and 0.05% Triton X-100 and then with 100 mM
sodium citrate buffer pH 3.00 containing 150 mM NaCl and 0.05%
Triton X-100. All buffers were prepared and used at 4 C. The elu-
ates were concentrated by methanol–chloroform precipitation and
analyzed on SDS–PAGE. Protein bands were stained with Coomas-
sie Brilliant Blue R-250 and compared to negative control samples
obtained by repeating the above protocol using a blank column of
inactivated NHS-Sepharose. Bands speciﬁcally retained on cathep-
sin K/E-64-Sepharose were excised from the gels and sent to the
Functional Genomics Center Zürich for identiﬁcation by mass
spectrometry.
2.3. Kinetic measurements
All measurements were performed with Z-Phe-Arg-AMC as sub-
strate in 50 mM Hepes buffer pH 7.40 supplemented with 1 mM
EDTA and 2.5 mMdithiothreitol (DTT) in single-use acrylic cuvettes
(1  1 cm) at 25 C with magnetic stirring. Reaction progress was
monitored continuously at kex 383 nmand kem 455 nm. The ﬁnal en-
zyme concentration in the assays was 0.1 nM of titrated active sites
and the total substrate consumption during the measuring time in
all experiments was less than 10%. Clusterin was added to the reac-
tion mixture just prior to each measurement and reactions were
started by addition of enzyme. The kinetic models are described in
the Theory section. Non-linear regression analysis was performed
with GraphPad Prism 5.0 (GraphPad Software).2.4. Thermal stability of cathepsin K and other cysteine peptidases
All enzymes were incubated at 37 C in 50 mM Hepes buffer pH
7.40 containing 1 mM EDTA and 2.5 mM DTT in the presence or ab-
sence of 0.3 lM clusterin. Experiments with cathepsin K were
additionally performed in the presence of 5 mg/ml soluble ETNA-
elastin. All experiments were performed in Eppendorf Protein Lo-
Bind Tubes to minimize the adsorption of proteins on tube walls.
In all assays the ﬁnal enzyme concentration was 0.2 lM. Aliquots
were taken in regular time intervals and their residual activity
measured using the substrate Z-Phe-Arg-AMC (10 lM ﬁnal
concentration).Scheme 1.2.5. Theory – time-dependent inactivation of cathepsin K
Inactivation curves of cathepsin K had exponential proﬁles that
were ﬁtted with models describing exponential decay in one or
two phases. The two phase model corresponds to a mechanism
containing two distinct pathways for loss of enzyme activity. The
equations describing residual enzyme activity for each model are:
v ¼ v0  ekt ð1Þfor a one phase exponential decay, where k is the rate constant for
the loss of enzyme activity, and
v ¼ v0ða  ek1t þ ð1 aÞ  ek2tÞ ð2Þ
for two-phase exponential decay, where a is the fraction of mole-
cules that are inactivated by the ﬁrst pathway and k1 and k2 are rate
constants for each pathway.
2.6. Theory – the action of a liberator
A liberator has been deﬁned as ‘a substance which may liberate
the enzyme from the action of an inhibitor without affecting the
enzyme activity alone’ [13]. This deﬁnition was extended also to
include the neutralizing action towards activators. In this study
we found that clusterin acts as a liberator from inhibition of
cathepsin K by substrate with a mechanism that can be repre-
sented as shown in Scheme 1 (E = enzyme, S = substrate, P = prod-
uct and L = liberator).
While this mechanism represents an extension of the slow inhi-
bition of cathepsin K by substrate described previously [10], the
novelty with respect to the original deﬁnition of liberator is that
clusterin acts in the context of a slow, time-dependent inhibition
process. Assuming that substrate depletion during a given measur-
ing time can be neglected and that tight-binding interactions are
absent, the integrated rate equation for this system can be derived
as
½P ¼ vst þ vz  vsk ð1 e
ktÞ ð3Þ
Eq. (3) is the same as that originally published by Frieden in the
context of enzyme hysteresis [14] and later used for describing
the action of slow-acting enzyme inhibitors [15]. Progress curves
consist of an exponential phase followed by a linear steady-state,
as shown in Fig. 2A, to which Eq. (3) can be ﬁtted to calculate the
values of k, vz and vs. The frequency constant k for the mechanism
in Scheme 1 is deﬁned as
k ¼ k4 þ k4 ½S
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L
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. The reaction rates at time
zero (vz) and at steady-state (vs) are given by
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where the limiting rates are deﬁned as V ¼ k2½Et and VL ¼ k7½Et
([E]t = total enzyme active sites concentration) and K

si ¼ k4=k4.
1064 M. Novinec et al. / FEBS Letters 586 (2012) 1062–1066According to the liberator concept, clusterin did not affect enzyme
activity when added alone to cathepsin K, meaning that in
Scheme 1 k6 ¼ k1; k6 ¼ k1 and k7 ¼ k2, hence in Eqs. (4) through
(6) KLm ¼ Km and VL ¼ V . Using these relationships Eqs. (4) through
(6) can be simpliﬁed to give
k ¼ k4 þ k4 ½S
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vs ¼




þ Km 1þ ½LKL 1þ
½S
Km
 h i ð9Þ3. Results
3.1. Afﬁnity chromatography
The goal of our work was to identify and to characterize extra-
cellular cathepsin K binding partners that bind outside of the active
site. For this purpose, the active site of cathepsin K was blocked
with the irreversible inhibitor E-64 to prevent its interaction with
protein substrates and the enzyme was then immobilized on NHS-
activated Sepharose. As the biological material of choice, human
blood serum was applied to this column and bound proteins eluted
by reducing the pH to 5.00 and successively to 3.00. Fig. 1 shows
fractions eluted from cathepsin K/E-64-Sepharose in comparison
to a blank control column. The major band retained speciﬁcally
on cathepsin K/E-64-Sepharose had an apparent molecular mass
of 35–40 kDa and was identiﬁed by mass spectrometry as the pro-
tein clusterin. In addition, several minor speciﬁcally retained bands
were observed, these proteins could however not be unambigu-
ously identiﬁed.
3.2. Effect on cathepsin K stability
The results presented above indicate that clusterin is a cathep-
sin K-binding protein that binds the enzyme at a site other than the
active site. To verify the functional signiﬁcance of this interactionFig. 1. Cathepsin K/E-64 afﬁnity chromatography. Fraction of human serum eluted
from cathepsin K/E-64-Sepharose at pH 5.00 and pH 3.00 (eluate) in comparison to
control samples eluted from a column without immobilized cathepsin K. The
strongest band speciﬁcally retained on cathepsinK/E-64-Sepahrose was identiﬁed
as clusterin (Clu) (marked by arrow).we have studied the activity and stability of the enzyme in the
presence of puriﬁed clusterin. The major effect observed was on
the stability of cathepsin K at physiological plasma pH, as deter-
mined by measuring residual enzyme activity after incubation of
the enzyme in dilute solution at 37 C. The plots of residual enzyme
activity are shown in Fig. 2 and the corresponding rate constants
and half-lives are collected in Table 1. The inactivation of cathepsin
K alone had a single exponential proﬁle (Fig. 2A), which can be
attributed mostly to autoproteolytic degradation of the enzyme
[10]. The presence of clusterin (added in 1.5-fold excess over the
enzyme) signiﬁcantly increased the stability of cathepsin K. Under
these conditions the activity proﬁle was best described with a two
phase exponential function, indicating that in the presence of clus-
terin loss of enzyme activity occurs in multiple phases that are
functionally distinct.
To simulate conditions in vivo and also to minimize the effect of
clusterin acting as a non-speciﬁc substrate, the stabilizing effect of
clusterin was re-tested in the presence of a high concentration of
protein (5 mg/ml soluble bovine neck ligament elastin) (Fig. 2B).
The residual enzyme activity curves obtained under these condi-
tions (with and without clusterin, respectively) could be described
by one phase exponential proﬁles. As reported previously [10], the
stability of cathepsin K was much higher in the presence of a mac-
romolecular substrate than in dilute solution (Table 1). Clusterin
was highly effective as a stabilizer under these conditions, result-
ing in an additional ﬁvefold increase in the half-life of cathepsin K.
To ascertain whether the effect of clusterin is speciﬁc for
cathepsin K or clusterin acts as a stabilizer of cysteine cathepsins
in general, we have repeated the experiments with other cathepsin
L-like peptidases (cathepsins L, V and S) as well as cathepsin B. In
all cases the presence of clusterin had no effect on the stability or
activity of the tested peptidases, demonstrating that clusterin is a
speciﬁc effector of cathepsin K and not a general cysteine
cathepsin-binding protein.3.3. Effect on cathepsin K activity
We have reported previously that cathepsin K can exist in mul-
tiple conformations that can be readily manipulated in vitro and is
affected by glycosaminoglycans that act as non-essential activators
of the enzyme [10]. The effect of clusterin on cathepsin K however
is not as straightforward. Clusterin affects the conformational ﬂex-
ibility of the enzyme in vitro, it is however necessary to establish
suitable experimental conditions for this effect to become appar-
ent. Our experiments indicate that binding of clusterin stabilizes
the conformation of cathepsin K in vitro but does not trigger a con-
formational change per se. Clusterin prevents the effect of slow
substrate inhibition which occurs at high substrate concentrations
and is manifested in the form of progress curves with exponential
proﬁles (Fig. 3A). In this respect the action of clusterin is conceptu-
ally similar to that of a liberator [13], a substance that reverses the
action of an inhibitor without itself exhibiting a direct effect on en-
zyme activity. The mechanism used for the treatment of experi-
mental data is found in the Theory section. Equilibrium constants
calculated with this model from experimental data (Fig. 3B and
C, respectively) show that clusterin binds cathepsin K with high
afﬁnity (KD values in the subnanomolar range shown in Fig. 3).
In addition to these experiments, we tested whether binding of
clusterin interferes with the binding of chondroitin sulfate and/or
dextran sulfate, which bind at two distinct sites on cathepsin K
and modify its kinetic properties [10]. Activity measurements have
shown that clusterin does not affect the speciﬁc effects of either
polyanion on cathepsin K, indicating that clusterin binds cathepsin
K at a site distinct from both identiﬁed binding sites for glycosami-
noglycans and does not interfere with their function.
Fig. 2. Effect of clusterin on the stability of cathepsin K in dilute solution (panel A) and in the presence of a high protein concentration (panel B). The enzyme (ﬁnal
concentration 0.2 lM) was incubated in 50 mM Hepes pH 7.40 containing 1 mM EDTA and 2.5 mM DTT at 37 C with shaking on an Eppendorf Thermomixer Compact.
Residual activity against Z-Phe-Arg-AMC was measured at regular time intervals. Solid lines represent best-ﬁt models of Eqs. (1) or (2) to the experimental data, as described
in the text.
Table 1
Half-life of cathepsin K at physiological plasma pH and at 37 C in the presence and absence of clusterin. The enzyme (E, 0.2 lM ﬁnal concentration) was incubated either alone, in
the presence of clusterin (0.5 lM ﬁnal concentration), in the presence of soluble ETNA elastin (5 mg/mL), or with both clusterin and elastin at the same concentrations. The buffer
was 50 mM Hepes pH 7.40 containing 1 mM EDTA and 2.5 mM DTT. Residual activity against Z-Phe-Arg-AMC was measured at regular time intervals.
Half life fast (min) Percent fast Half life slow (min) Percent slow
Enzyme only 7.0 ± 0.7 100 – –
Enzyme + clusterin 15 ± 2 82 100 ± 15 18
Enzyme + elastin 32 ± 2 100 – –
Enzyme + elastin + clusterin 167 ± 8 100 – –
Fig. 3. Effect of clusterin on the conformational ﬂexibility of cathepsin K in vitro. (A) Representative examples of progress curves. (B) The dependence of the liberator effect on
the concentration of clusterin. The solid line represents the best ﬁt of Eq. (8) to experimental data. (C) Dependence of the frequency constant on the concentration of clusterin.
The solid line represents the best ﬁt of Eq. (3) to experimental data. All experiments were performed in 50 mM Hepes pH 7.40 containing 1 mM EDTA and 2.5 mM DTT at
25 C. The enzyme was preincubated in the same buffer supplemented with 300 mM NaCl. The substrate used was Z-Phe-Arg-AMC (ﬁnal concentration 10 lM).
M. Novinec et al. / FEBS Letters 586 (2012) 1062–1066 10654. Discussion
It was long accepted that proteinaceous macromolecular inhib-
itors are the major mechanism for cysteine cathepsin regulation
inside and outside of the cell. However, work done in the last dec-
ade has pointed out the importance of other, complementary
mechanisms for the regulation of these enzymes. Cathepsin K is
attracting considerable attention due to its involvement in physio-
logical and pathological bone resorption [6] and glycosaminogly-
cans have been shown to play a major role in the regulation of
its activity in the extracellular space [10,11].
In this paper we expand the scheme of extracellular cathepsin K
regulation by describing clusterin as a cathepsin K-binding protein.
Clusterin has been mostly studied for the contradictive roles of its
isoforms in apoptosis and tumor progression [16] and its role as
an extracellular chaperone [17]. The ability of clusterin to bind a
wide variety of stressed proteins has been described [18] and it
was also shown to bind unstressed ligands via distinct binding sites
[19]. In our experiments, clusterin did not directly affect enzyme
activity but instead increased the stability of cathepsinK and altered
its conformational ﬂexibility in vitro. The action of clusterin as aliberator from enzyme inhibition by excess substrate, discovered
in this study with the non-natural Z-Phe-Arg-AMC substrate, dem-
onstrates the existence of an additional exosite on the enzymemol-
ecule. This region, which is different from the previously identiﬁed
binding site for glycosaminoglycans [10], may represent a regula-
tory element for interaction with substrates and effectors in vivo.
These ﬁndings support the theory of clusterin acting as an extracel-
lular chaperone. Moreover, we have shown that clusterin indeed
can stabilize enzyme activity, whichwas not observedwith catalase
and glutathione-S-transferase [20]. The effect of clusterin on
cathepsin K was unique among cysteine cathepsins since other
members of this group were not affected by its presence in terms
of stability or activity.
The equilibrium constant calculated in vitro indicates that bind-
ing of clusterin and cathepsin K is relatively tight, indicating that
complex formation is likely to occur in vivo. Altogether, our results
suggest a predominantly stabilizing role in the regulation of
cathepsin K with minor effects on enzyme activity, indicating that
it may protect the enzyme from denaturation before reaching its
target sites. Since binding of clusterin does not exclude the binding
of GAGs, which act as activators of cathepsin K [10], ternary com-
1066 M. Novinec et al. / FEBS Letters 586 (2012) 1062–1066plex formation with increased activity and stability may also be
possible. Altogether the ﬁndings presented in this paper add an
additional layer of complexity to the regulatory mechanisms for
cysteine cathepsin activity in the extracellular space.
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